KAMURAStrong trials for specific manufactured medicines
Evidence must match the specific medicine, dose, population and studied outcome.
Compounded GLP-1 (semaglutide, tirzepatide)
The branded medicines have strong trial evidence. A compounded copy is a different product: same intended molecule, but without the manufacturer testing, the device, or the dose-accuracy guarantees behind that evidence.
Compounded preparations do not inherit product approval
Check the exact ingredients, delivery route and preparation. An ingredient study does not establish the performance of every blend.
compounded semaglutide · compounded tirzepatide · weight-loss injection · generic Ozempic
What is it?
A pharmacy-prepared version of a GLP-1 receptor agonist, usually supplied in a vial with a separate syringe rather than a pre-filled pen. Some versions use salt forms of the molecule that were never in the clinical trials.
Why this formulation?
Almost always cost and availability. During shortages, compounded versions filled a gap. That is a supply argument, not a clinical one — and regulators in several countries have restricted it as supply recovered.
What can the research tell us?
For the branded, manufactured medicines the evidence is genuinely strong: large randomised trials showing substantial weight loss and, for semaglutide, cardiovascular benefit. That evidence belongs to those specific products at those specific doses. It does not automatically transfer to a compounded copy, where concentration, salt form, sterility and stability are not verified by the original manufacturer. Dosing errors have been reported where people measure from a vial rather than dial a pen.
Read the supporting sources ↓What to discuss about alternatives
If a GLP-1 is clinically appropriate for you, the first question is whether you can access the approved product. Compounded should be a considered fallback with eyes open, not an equivalent choice — and never a cosmetic one for someone without a metabolic indication.
Contexts to discuss with a clinician
- Obesity or type 2 diabetes management, under medical supervision — normally with the approved product where it is available
Details worth checking
- Measuring from a vial with an unfamiliar syringe — a leading source of accidental overdose
- Salt forms such as semaglutide acetate, which were not the trial molecule
- Sold without any medical assessment, or shipped from an unlicensed source
- Marketing to people with no metabolic indication at all
Build your appointment questions.
Select the questions you want to take to your appointment.
Sources & further reading
FDA: Concerns with unapproved GLP-1 medicines ↗Differences in approval, salt forms, storage and dosing errors. US context.
FDA: Compounding and GLP-1 supply ↗US supply and compounding policy; local requirements need separate confirmation.
These sources explain the evidence and its scope. Regulatory sources describe their own jurisdiction; they are not a statement of UAE prescribing or pharmacy rules.